Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Malcolm MacCoss

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
The Journal of Biological Chemistry|January 30, 2003
Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogsSteven S Carroll, Joanne E Tomassini, Michele Bosserman, et al.
Journal of Medicinal Chemistry|May 16, 2009
Discovery of N-{N-[(3-cyanophenyl)sulfonyl]-4(R)-cyclobutylamino-(L)-prolyl}-4-[(3',5'-dichloroisonicotinoyl) amino]-(L)-phenylalanine (MK-0668), an extremely potent and orally active antagonist of very late antigen-4Linus S Lin, Thomas Lanza, James P Jewell, et al.
Bioorganic & Medicinal Chemistry Letters|February 3, 2005
Synthesis and evaluation of CCR5 antagonists containing modified 4-piperidinyl-2-phenyl-1-(phenylsulfonylamino)-butaneShrenik K Shah, Natalie Chen, Ravindra N Guthikonda, et al.
Bioorganic & Medicinal Chemistry Letters|September 25, 2002
1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 3: polar functionality and its effect on anti-HIV-1 activityJeffrey J Hale, Richard J Budhu, Sander G Mills, et al.
Bioorganic & Medicinal Chemistry Letters|June 5, 2004
Syntheses and SAR studies of 4-(heteroarylpiperdin-1-yl-methyl)-pyrrolidin-1-yl-acetic acid antagonists of the human CCR5 chemokine receptorK Shankaran, Karla L Donnelly, Shrenik K Shah, et al.
Bioorganic & Medicinal Chemistry Letters|December 13, 2005
The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infectionYusheng Xiong, Judyann Wiltsie, Andrea Woods, et al.
Journal of Medicinal Chemistry|April 16, 2004
Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymeraseAnne B Eldrup, Charles R Allerson, C Frank Bennett, et al.
Bioorganic & Medicinal Chemistry Letters|July 13, 2006
Cyclopentane-based human NK1 antagonists. Part 2: development of potent, orally active, water-soluble derivativesLaura C Meurer, Paul E Finke, Karen A Owens, et al.
Bioorganic & Medicinal Chemistry Letters|April 6, 2005
Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic propertiesDooseop Kim, Liping Wang, Jeffrey J Hale, et al.
Bioorganic & Medicinal Chemistry Letters|February 15, 2002
CCR5 antagonists: bicyclic isoxazolidines as conformationally constrained N-1-substituted pyrrolidinesChristopher L Lynch, Amy L Gentry, Jeffrey J Hale, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
The Journal of Biological Chemistry|January 30, 2003
Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogsSteven S Carroll, Joanne E Tomassini, Michele Bosserman, et al.
Journal of Medicinal Chemistry|May 16, 2009
Discovery of N-{N-[(3-cyanophenyl)sulfonyl]-4(R)-cyclobutylamino-(L)-prolyl}-4-[(3',5'-dichloroisonicotinoyl) amino]-(L)-phenylalanine (MK-0668), an extremely potent and orally active antagonist of very late antigen-4Linus S Lin, Thomas Lanza, James P Jewell, et al.
Bioorganic & Medicinal Chemistry Letters|February 3, 2005
Synthesis and evaluation of CCR5 antagonists containing modified 4-piperidinyl-2-phenyl-1-(phenylsulfonylamino)-butaneShrenik K Shah, Natalie Chen, Ravindra N Guthikonda, et al.
Bioorganic & Medicinal Chemistry Letters|September 25, 2002
1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 3: polar functionality and its effect on anti-HIV-1 activityJeffrey J Hale, Richard J Budhu, Sander G Mills, et al.
Bioorganic & Medicinal Chemistry Letters|June 5, 2004
Syntheses and SAR studies of 4-(heteroarylpiperdin-1-yl-methyl)-pyrrolidin-1-yl-acetic acid antagonists of the human CCR5 chemokine receptorK Shankaran, Karla L Donnelly, Shrenik K Shah, et al.
Bioorganic & Medicinal Chemistry Letters|December 13, 2005
The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infectionYusheng Xiong, Judyann Wiltsie, Andrea Woods, et al.
Journal of Medicinal Chemistry|April 16, 2004
Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymeraseAnne B Eldrup, Charles R Allerson, C Frank Bennett, et al.
Bioorganic & Medicinal Chemistry Letters|July 13, 2006
Cyclopentane-based human NK1 antagonists. Part 2: development of potent, orally active, water-soluble derivativesLaura C Meurer, Paul E Finke, Karen A Owens, et al.
Bioorganic & Medicinal Chemistry Letters|April 6, 2005
Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic propertiesDooseop Kim, Liping Wang, Jeffrey J Hale, et al.
Bioorganic & Medicinal Chemistry Letters|February 15, 2002
CCR5 antagonists: bicyclic isoxazolidines as conformationally constrained N-1-substituted pyrrolidinesChristopher L Lynch, Amy L Gentry, Jeffrey J Hale, et al.
Pageof 7